This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bodurka, D. C. Articles by Gershenson, D. M. Search for Related Content PubMed PubMed Citation Articles by Bodurka, D. C. Articles by Gershenson, D. M. Social Bookmarking                            What's this?

Phase II Trial of Irinotecan in Patients With Metastatic Epithelial Ovarian Cancer or Peritoneal Cancer

Diane C. Bodurka, Charles Levenback, Judith K. Wolf, Jacalyn Gano, J. Taylor Wharton, John J. Kavanagh, David M. Gershenson

From the Departments of Gynecologic Oncology and Gynecologic and Medical Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

Address reprint requests to Diane C. Bodurka, MD, Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 440, Houston, TX 77030; email: dcbodurka{at}mdanderson.org.

Purpose: To evaluate the efficacy and toxicity of irinotecan in patients with metastatic platinum-resistant or platinum-refractory epithelial ovarian cancer or primary peritoneal cancer.

Patients and Methods: Thirty-one patients with measurable disease were enrolled in our study at The University of Texas M.D. Anderson Cancer Center. Twenty-five of these patients were treated with irinotecan at a dose of 300 mg/m² intravenously for 90 minutes every 3 weeks; the remaining six patients were treated with 250 mg/m² because their age was greater than 65 years. Median age was 57 years (range, 38 to 74 years). The majority (84%) had a Zubrod performance status of 0. All patients were evaluated for irinotecan toxicity, and 29 (94%) were evaluable for response.

Results: The overall response rate was 17.2%. One patient (3%) had a complete response, four (14%) had partial responses, 14 (48%) had stable disease, and 10 had (35%) disease progression. Median progression-free survival was 2.8 months (range, 1.1 to 16 months), median duration of response was 1.4 months (range, 0.7 to 10.1 months); median survival from primary diagnosis was 24.3 months (range, 6.5 to 85.7 months); and median survival from initiation of irinotecan was 10.1 months (range, 2.3 to 34 months). Major toxicities included fatigue (16 patients), neutropenia (11 patients), diarrhea (nine patients), nausea (10 patients), and anorexia (seven patients). Eleven patients required dose reductions because of these toxicities. No treatment-related deaths occurred.

Conclusion: Irinotecan has moderate efficacy and substantial toxicity in patients with metastatic platinum-resistant or platinum-refractory epithelial ovarian or primary peritoneal cancer.

Supported by Pharmacia & Upjohn, Inc., Peapack, NJ.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Nagano, M. Yasunaga, K. Goto, H. Kenmotsu, Y. Koga, J.-i. Kuroda, Y. Nishimura, T. Sugino, Y. Nishiwaki, and Y. Matsumura Antitumor Activity of NK012 Combined with Cisplatin against Small Cell Lung Cancer and Intestinal Mucosal Changes in Tumor-Bearing Mouse after Treatment Clin. Cancer Res., July 1, 2009; 15(13): 4348 - 4355. [Abstract] [Full Text] [PDF]

				Y. Matsumura Polymeric Micellar Delivery Systems in Oncology Jpn. J. Clin. Oncol., December 1, 2008; 38(12): 793 - 802. [Abstract] [Full Text] [PDF]

				M. Markman New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian Cancer Oncologist, February 1, 2007; 12(2): 186 - 190. [Abstract] [Full Text] [PDF]

				F. Koizumi, M. Kitagawa, T. Negishi, T. Onda, S.-i. Matsumoto, T. Hamaguchi, and Y. Matsumura Novel SN-38-Incorporating Polymeric Micelles, NK012, Eradicate Vascular Endothelial Growth Factor-Secreting Bulky Tumors. Cancer Res., October 15, 2006; 66(20): 10048 - 10056. [Abstract] [Full Text] [PDF]

				P. Sabbatini, C. Aghajanian, D. Dizon, S. Anderson, J. Dupont, J. V. Brown, W. A. Peters, A. Jacobs, A. Mehdi, S. Rivkin, et al. Phase II Study of CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma J. Clin. Oncol., November 15, 2004; 22(22): 4523 - 4531. [Abstract] [Full Text] [PDF]

				L. M. Wagner, K. R. Crews, L. C. Iacono, P. J. Houghton, C. E. Fuller, M. B. McCarville, R. E. Goldsby, K. Albritton, C. F. Stewart, and V. M. Santana Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors Clin. Cancer Res., February 1, 2004; 10(3): 840 - 848. [Abstract] [Full Text] [PDF]

				H. Hochster, E. R. Plimack, C. D. Runowicz, J. Speyer, R. C. Wallach, J. Sorich, J. Mandeli, S. Wadler, J. Wright, and F. M. Muggia Biweekly 72-Hour 9-Aminocamptothecin Infusion As Second-Line Therapy for Ovarian Carcinoma: Phase II Study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group J. Clin. Oncol., January 1, 2004; 22(1): 120 - 126. [Abstract] [Full Text] [PDF]